Title:
COMPOUND FOR TREATING THROMBOTIC DISEASES
Document Type and Number:
WIPO Patent Application WO/2022/017531
Kind Code:
A1
Abstract:
The present invention relates to a compound for treating thrombotic diseases. Specifically, the present invention provides a compound represented by formula I, or a pharmaceutically acceptable salt, or an enantiomer, or a diastereoisomer, or an atropisomer, or a racemate, or a polymorph, or a solvate, or an isotopically labeled derivative thereof. The compound disclosed in the present invention can be specifically combined with SH3 domain protein of Src kinase and then interfere the combination of integrin αIIbβ3 and Src kinase, so that outside-to-inside signal transduction is selectively inhibited and inside-to-outside signal transduction is not influenced; thus, while resisting thrombus, the compound of the present invention does not affect the normal physiological hemostatic function, prevents the occurrence of hemorrhagic side effect, and can be used as a new generation of effective medicine for preventing and treating thrombosis-related cardiovascular and cerebrovascular diseases.
Inventors:
LUO CHENG (CN)
XI XIAODONG (CN)
ZHOU BING (CN)
ZHU KONGKAI (CN)
MAO JIANHUA (CN)
LIU JINGQIU (CN)
YANG YAXI (CN)
MEI LIANGHE (CN)
RUAN ZHENG (CN)
JIANG HAO (CN)
XI WENDA (CN)
LONG ZHANGBIAO (CN)
XIAO BING (CN)
HUANG JIANSONG (CN)
JIANG HUALIANG (CN)
XI XIAODONG (CN)
ZHOU BING (CN)
ZHU KONGKAI (CN)
MAO JIANHUA (CN)
LIU JINGQIU (CN)
YANG YAXI (CN)
MEI LIANGHE (CN)
RUAN ZHENG (CN)
JIANG HAO (CN)
XI WENDA (CN)
LONG ZHANGBIAO (CN)
XIAO BING (CN)
HUANG JIANSONG (CN)
JIANG HUALIANG (CN)
Application Number:
PCT/CN2021/108368
Publication Date:
January 27, 2022
Filing Date:
July 26, 2021
Export Citation:
Assignee:
SHANGHAI INST MATERIA MEDICA CAS (CN)
RUIJIN HOSPITAL SHANGHAI JIAOTONG UNIV SCHOOL MEDICINE (CN)
SUZHOU INSTITUTE OF MATERIA MEDICA CHINA SCIENCE AND TECH (CN)
RUIJIN HOSPITAL SHANGHAI JIAOTONG UNIV SCHOOL MEDICINE (CN)
SUZHOU INSTITUTE OF MATERIA MEDICA CHINA SCIENCE AND TECH (CN)
International Classes:
A61K31/343; C07D471/04; A61K31/381; A61K31/40; A61K31/519; A61P9/00; C07D209/12; C07D307/79; C07D311/04; C07D333/56; C07D491/048; C07D493/04; C07D495/04
Domestic Patent References:
| WO2019078246A1 | 2019-04-25 |
Foreign References:
| US20040171073A1 | 2004-09-02 | |||
| CN1498214A | 2004-05-19 | |||
| US4260628A | 1981-04-07 | |||
| US3855242A | 1974-12-17 | |||
| CN101172997A | 2008-05-07 | |||
| CN200610117991A | 2006-11-03 |
Other References:
FADEEVA N. I., LENEVA I. L., PANISHEVA E. K., BUSSE T. L., KHRISTOVA M. L., KHARITONENKOV I. G., GRANIK V. G.: "Inhibitors of the early stages of virus-cell interactions among derivatives of 3-ethoxycarbonyl-5-hydroxy-6-bromoindole", PHARMACEUTICAL CHEMISTRY JOURNAL, vol. 26, no. 9-10, 1 September 1992 (1992-09-01), US , pages 676 - 680, XP055888942, ISSN: 0091-150X, DOI: 10.1007/BF00770609
XIE, MEIHUA ET AL.: "Antihypertensive Drugs: Synthesis of Quaternary Ammonium Salts and Guanidine Derivatives of Thiophene, Furan and Benzofuran", ACTA PHARMACEUTICA SINICA, vol. 17, no. 3, 31 March 1982 (1982-03-31), pages 229 - 232, XP055888952
T.GREENEP. WUTS: "Protecting Groups in Chemical Synthesis", 1999, JOHN WILEY & SONS
XIE, MEIHUA ET AL.: "Antihypertensive Drugs: Synthesis of Quaternary Ammonium Salts and Guanidine Derivatives of Thiophene, Furan and Benzofuran", ACTA PHARMACEUTICA SINICA, vol. 17, no. 3, 31 March 1982 (1982-03-31), pages 229 - 232, XP055888952
T.GREENEP. WUTS: "Protecting Groups in Chemical Synthesis", 1999, JOHN WILEY & SONS
Attorney, Agent or Firm:
XU & PARTNERS, LLC. (CN)
Download PDF:
Previous Patent: USE OF COMPOUND INTERFERING WITH INTEGRIN βETA3/SRC INTERACTION
Next Patent: C-SRC SH3 RT-LOOP AS TARGET FOR RESISTING THROMBUS
Next Patent: C-SRC SH3 RT-LOOP AS TARGET FOR RESISTING THROMBUS